|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Cross-tabulation analysis showed that the expression level of miR-100 was significantly associated with patients' age, TNM stage, metastasis and histological type (P<0.05), but not with sex (P>0.05).
|
31423192 |
2019 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Interfering miR-100 expression of TAMs in mouse breast cancer model could inhibit TAMs pro-tumor function and reduce tumor metastasis, which suggests that miR-100 could serve as a potential therapy target to remodel tumor microenvironment in breast cancer.
|
30563983 |
2018 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
MicroRNA microarray analysis revealed that miR-100 and miR-125b expression levels were significantly lower in CRC tissues with lymph node metastases than in those without metastases.
|
28032929 |
2017 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Taken together, our findings imply that miR-125b and miR-100 negatively regulate Angpt2 expression through different mechanisms, in turn inhibit VETC formation, and consequently abrogate the VETC-dependent metastasis of hepatoma cells.
|
27577856 |
2016 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Overexpression of miR-100 suppressed tumor growth in vivo and inhibited gastric cancer invasion and metastasis in vitro and in vivo.
|
26404754 |
2015 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Downregulation of miR-100 contributes to HCC metastasis and the restoration of miR-100 is a potential strategy for cancer therapy.
|
25361001 |
2014 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Additionally, low miR-100 expression in ESCC tissues was significantly associated with the advanced clinical stage (P = 0.008), the presence of distant metastasis (P = 0.008), and the great depth of invasion (P = 0.02).
|
25218280 |
2014 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
However, it is unknown whether and how miR-100 and AGO2 regulates metastasis of prostate cancer.
|
24805183 |
2014 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
In addition, the cancerous metastatic nude mouse model established on the basis of primary bladder cancer cell lines suggested that miR-100/mTOR regulated cell motility and was associated with tumor metastasis.
|
23270926 |
2013 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
In addition, high miR-100 expression in RCC tissues was significantly associated with advanced tumor T stage (P = 0.005) and grade (P = 0.01), and the presence of metastasis (P = 0.008).
|
23378187 |
2013 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis.
|
19372056 |
2011 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines.
|
19487542 |
2009 |
|
Bladder Neoplasm
|
0.380 |
Biomarker
|
disease |
BEFREE |
We assessed a quantitative RT-PCR analysis of miR-100 and miR-138 in 50 bladder tumor samples (stage Ta/T1) and four healthy adjacent tissues.
|
31231851 |
2019 |
|
Bladder Neoplasm
|
0.380 |
Biomarker
|
disease |
CTD_human |
A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder.
|
30026881 |
2018 |
|
Bladder Neoplasm
|
0.380 |
Biomarker
|
disease |
BEFREE |
In addition, the association between miR-100 and prognosis was also revealed in the following subgroups: non-small-cell lung cancer (NSCLC; HR =2.46; 95% CI =1.98-3.06), epithelial ovarian cancer (EOC; HR =2.29, 95% CI =1.72-3.04), and bladder cancer (BC; HR =4.14, 95% CI =1.85-9.27).
|
28176958 |
2017 |
|
Bladder Neoplasm
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
The aim of our study was to identify plasma miR-92a, miR-100 and miR-143 expression signatures in patients with BC to introduce new markers for establishing BC diagnosis and prognosis.
|
26916216 |
2016 |
|
Bladder Neoplasm
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
miR-182 was upregulated in BCa and miR-100 was down-regulated in BCa compared with NBE (P < 0.001).
|
27631180 |
2016 |
|
Bladder Neoplasm
|
0.380 |
Biomarker
|
disease |
BEFREE |
The present study demonstrated that the downregulation of miR-100 was associated with advanced clinical features and poor prognosis for bladder cancer patients, suggesting that miR-100 downregulation may be used as an unfavorable prognostic biomarker in bladder cancer.
|
26662386 |
2015 |
|
Bladder Neoplasm
|
0.380 |
Biomarker
|
disease |
BEFREE |
Taken together, miR-100 may act as a tumor suppressor in bladder cancer, and reintroduction of this mature miRNA into tumor tissue may prove to be a therapeutic strategy by reducing the expression of target genes.
|
23270926 |
2013 |
|
Bladder Neoplasm
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Bladder cancer cell lines were exposed to normoxic or hypoxic conditions and examined for the expression of FGFR3 by quantitative PCR (qPCR) and western blotting, and miR-100 by qPCR.
|
23778527 |
2013 |
|
Bladder Neoplasm
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
When categorized into low vs. high expression, low miR-100 expression was negatively associated with the stage (P = 0.01), the recurrence (P = 0.008), the progression (P = 0.01), and the death (P < 0.001) of patients with bladder cancer.
|
23173870 |
2012 |
|
Malignant neoplasm of urinary bladder
|
0.370 |
Biomarker
|
disease |
CTD_human |
A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder.
|
30026881 |
2018 |
|
Malignant neoplasm of urinary bladder
|
0.370 |
Biomarker
|
disease |
BEFREE |
In addition, the association between miR-100 and prognosis was also revealed in the following subgroups: non-small-cell lung cancer (NSCLC; HR =2.46; 95% CI =1.98-3.06), epithelial ovarian cancer (EOC; HR =2.29, 95% CI =1.72-3.04), and bladder cancer (BC; HR =4.14, 95% CI =1.85-9.27).
|
28176958 |
2017 |
|
Malignant neoplasm of urinary bladder
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
The aim of our study was to identify plasma miR-92a, miR-100 and miR-143 expression signatures in patients with BC to introduce new markers for establishing BC diagnosis and prognosis.
|
26916216 |
2016 |
|
Malignant neoplasm of urinary bladder
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
miR-182 was upregulated in BCa and miR-100 was down-regulated in BCa compared with NBE (P < 0.001).
|
27631180 |
2016 |